NCT00859339 - Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Transitional Cell Carcinoma of the Bladder

Interventions

DRUG

Gemcitabine

Gemcitabine ( 1000 mg/m2) IV days 1 and 8

DRUG

Cisplatin

Cisplatin (70 mg/m2) IV day 1

DRUG

Sunitinib Malate

Sunitinib malate (37.5 mg) oral daily for days 1-14

PROCEDURE

Radical Cystectomy

Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.

Trial Locations (5)

University of Florida, Gainesville

Indiana University Simon Cancer Center, Indianapolis

Northern Indiana Cancer Research Consortium, South Bend

Baylor College of Medicine, Houston

St. Bartholomew's Hospital (Barts), London